subscribe now
Not getting email updates?

Perspective on the Rx Pipeline: A Summary of Impactful Changes

May 3, 2018

EnvisionRx continuously monitors the drug pipeline. Our team evaluates changing treatment options in order to educate and inform our clients on the most impactful medications in development, new drugs recently approved, generics being launched and current medications receiving new indications.

Clinical Pipeline

Within the extensive pipeline of drugs preparing for market launch, three notable drugs plan sponsors should be aware of are:

  • Avatrombopag an oral medication for patients with thrombocytopenia (lower number of platelets) needing to undergo a procedure. Instead of an intravenous platelet transfusion, these patients will be able to take this pill to raise platelet counts.
  • Aimovig™ (erenumab) is set to be the first drug in a new class of medications known as calcitonin gene-related peptide (CGRP) antagonists used for the prevention of migraines. Current medications used to prevent migraines were not originally designed for this use and oftentimes require higher doses, which may cause intolerable adverse events.
  • Mogamulizumab for the treatment of cutaneous T-cell lymphoma (CTCL) is manufactured in Japan and, if approved in the U.S., would offer an option for patients who have failed on previous systemic therapies.

Drug Approvals

Two significant specialty drugs recently approved by the Food and Drug Administration (FDA) include:

  • Ilumya™ (tildrakizumab-asmn) for the treatment of plaque psoriasis
  • Trogarzo™ (ibalizumab-uiyk) for the treatment of HIV 

New Indications

Drugs that have gained FDA approval for the treatment of additional diseases and/or conditions and have potential to be impactful include:

  • Blincyto® (blinatumomab) was developed to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). In March, it was approved to treat minimal residual disease (MRD)-positive B-cell precursor ALL.
  • Tasigna® (nilotinib) was approved in October 2017 to treat adults with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and in March, was expanded to treat pediatric patients as well.
  • Adcetris® (brentuximab vedotin) treats relapsed and refractory Hodgkin lymphoma and was recently approved to also treat stage III or IV classical Hodgkin lymphoma.
  • Hizentra® (immune globulin subcutaneous (human)) for the treatment of primary humoral immunodeficiency was approved for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

Generic Approvals

There are several new generic product offerings to the marketplace, including a drug used to reduce nausea and vomiting for chemotherapy patients, a HIV medication and a birth control pill. A glimpse into the potential generic launches is included in the full report.

Download the full report for more information, including important safety updates and drug shortages and discontinuations.